Truist reiterates Rapport Therapeutics stock rating on trial data
Covered in this story
What has happened since
- Rapport Therapeutics Inc is down 14.7% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Truist Securities’s $56 target on $RAPP is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Truist Securities’s track record →Analyst targets on Rapport Therapeutics Inc
- Raymond James: $29.4 → $86 by Oct 2027 · Strong Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RAPP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Rapport Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.